Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 10, 2023 07:30 ET | Source: Organogenesis Holdings Inc.

Organogenesis Holdings Inc. to Report Second Quarter of Fiscal Year 2023 Financial Results on August 9, 2023

CANTON, Mass., July 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
May 10, 2023 16:05 ET | Source: Organogenesis Holdings Inc.

Organogenesis Holdings Inc. Reports First Quarter 2023 Financial Results

CANTON, Mass., May 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
April 27, 2023 07:30 ET | Source: Organogenesis Holdings Inc.

Organogenesis President and Chief Executive Officer Gary S. Gillheeney, Sr. Elected Chair of the Board of Directors

CANTON, Mass., April 27, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
April 10, 2023 07:30 ET | Source: Organogenesis Holdings Inc.

Organogenesis Holdings Inc. to Report First Quarter of Fiscal Year 2023 Financial Results on May 10, 2023

CANTON, Mass., April 10, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
March 27, 2023 08:00 ET | Source: Organogenesis Holdings Inc.

Organogenesis Applauds Findings from the Office of Inspector General

CANTON, Mass., March 27, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
March 01, 2023 16:02 ET | Source: Organogenesis Holdings Inc.

Organogenesis Holdings Inc. Reports Fourth Quarter 2022 and Fiscal Year 2022 Financial Results; Introduces Fiscal Year 2023 Guidance

CANTON, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
March 01, 2023 16:01 ET | Source: Organogenesis Holdings Inc.

Organogenesis Reports Positive Interim Analysis of Phase 3 Clinical Trial of ReNu for Knee Osteoarthritis

CANTON, Mass. , March 01, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
February 09, 2023 07:30 ET | Source: Organogenesis Holdings Inc.

Organogenesis Holdings Inc. to Report Fourth Quarter and Fiscal Year 2022 Financial Results on March 1, 2023

CANTON, Mass., Feb. 09, 2023 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization...
December 05, 2022 07:30 ET | Source: Organogenesis Holdings Inc.

Organogenesis Holdings Inc. to Participate in the Cantor Fitzgerald Medical and Aesthetic Dermatology, Ophthalmology and Medtech Conference

CANTON, Mass., Dec. 05, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...
November 09, 2022 16:05 ET | Source: Organogenesis Holdings Inc.

Organogenesis Holdings Inc. Reports Third Quarter 2022 Financial Results

CANTON, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Organogenesis Holdings Inc. (Nasdaq: ORGO), a leading regenerative medicine company focused on the development, manufacture, and commercialization of...